ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 24, 2014
Apple Is Back!
We never thought the firm left, but the media seemed to think so. Let’s dig into the iPhone-maker’s fiscal second-quarter performance.
Apr 23, 2014
Perhaps Nothing Stronger Than Aerospace
Boeing put up strong first-quarter results and showcased its massive backlog of unfulfilled orders.
Apr 23, 2014
Throwing In the Towel on Intuitive Surgical
Management no longer has the visibility it once had.
Apr 22, 2014
Big News in Big Pharma
Pfizer is looking to scoop up AstraZeneca, Valeant and Ackman eye Allergan, Eli Lilly and Novartis strike a deal in animal health, and Novartis picks up GSK’s oncology portfolio.
Apr 21, 2014
Restaurant Industry Update
Let’s take a look at some key developments in the restaurant space.
Apr 20, 2014
The Cola Wars: Currency Headwinds Intensify; Snacks Looking Better
Pepsi is slightly better positioned in 2014, but we like Coca-Cola better.
Apr 20, 2014
Dividend Increases for the Week Ending April 18
Let's take a look at dividend increases for the week ending April 18.
Apr 18, 2014
Google’s First-Quarter Performance: Business as Usual
Google posted strong results, but the market wanted more.
Apr 17, 2014
IBM Continues to Lose Its Luster
Big Blue is using share buybacks to hit earnings-per-share targets at the expense of economic value creation. This is low-quality performance, and we don’t think Warren Buffett, its largest holder, will tolerate such activity for much longer.
Apr 17, 2014
Expect Abbott to Raise Its 2014 Outlook Soon
Abbott’s first-quarter results weren’t pristine, but the company’s better-than-expected first-quarter performance will eventually lead to an upwardly-revised full-year outlook, in our view.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.